On September 1, 2022 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, reported that it will host a virtual investor event to review clinical data from the Company’s DCC-3116 and vimseltinib programs to be presented at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 on Sunday, September 11, 2022, from 7:30 AM to 9:30 AM ET / 1:30 PM CEST to 3:30 PM CEST (Press release, Deciphera Pharmaceuticals, SEP 1, 2022, View Source [SID1234618867]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Deciphera’s management team will be joined by the following key opinion leaders at the event:
Anthony W. Tolcher, M.D., CEO, Founder, and Director of Clinical Research at NEXT Oncology
Jean-Yves Blay, M.D., Ph.D., Medical Oncologist, General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon, France
The event may be accessed by registering at View Source A webcast of the event will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source The archived webcast will be available on the Company’s website within 24 hours after the event and will be available for 30 days following the event.
ESMO Congress 2022 Presentation Details:
Title: Initial monotherapy results of a phase 1 first‑in‑human study of ULK1/2 inhibitor DCC‑3116 alone and in combination with MAPK pathway inhibition
Presentation Number: 450O
Speaker: Anthony W. Tolcher, M.D.
Session Name: Proffered Paper Session – Developmental Therapeutics
Date: Saturday, September 10, 2022
Time: 11:05 AM to 11:15 AM CEST
Location: Orléans Auditorium
Title: Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase 2 expansion
Presentation Number: 1509P
Speaker: Jean-Yves Blay, M.D., Ph.D.
Session Name: Poster – Sarcoma
Date: Sunday, September 11, 2022
Time: All day; author available 12 PM to 1 PM CEST
Location: Hall 4
Title: Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase 1 update
Presentation Number: 475P
Speaker: Hans Gelderblom, M.D., Ph.D.
Session Name: Poster – Developmental Therapeutics
Date: Monday, September 12, 2022
Time: All day; author available 12 PM to 1 PM CEST
Location: Hall 4